Pharmacokinetic Interaction Between DWP14012 and DWC202005 in Healthy Volunteers

An Open-Label, Multiple-Dose Clinical Trial to Evaluate the Safety/Tolerability and Pharmacokinetic Interaction Between DWP14012 and DWC202005 in Healthy Volunteers

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04328766

Enrollment

Registered

2020-03-31

Start date

2020-09-06

Completion date

2020-11-21

Last updated

2021-08-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Drug-drug Interaction

Brief summary

An open-label, multiple-dose clinical trial to evaluate the safety/tolerability and pharmacokinetic interaction between DWP14012 and DWC202005 in healthy volunteers

Interventions

DRUGDWC202005, alone

DWC202005, as a single dose

DRUGDWP14012 + DWC202005

DWP14012 and DWC202005, as a single dose

DRUGDWP14012 + DWC202005, after multiple doses of DWP14012

DWP14012 and DWC202005, after multiple oral doses of DWP14012 once daily for 12 days

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

19 Years to 50 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy adults aged 19 to 50 years with BMI between 18.5 kg/m2 and 30.0 kg/m2 * Capable of understanding provided information and complying with protocol requirements * Provide written informed consent to participate in the study

Design outcomes

Primary

Measure	Time frame	Description
Incidence of Treatment-Emergent Adverse Events	up to 19 days	—
Area under the plasma drug concentration-time curve	upto 48 hours postdose	AUClast of DWC202005
Peak Plasma Concentration (Cmax)	upto 48 hours postdose	Cmax of DWC202005

Countries

Australia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026